Mentari Therapeutics closes InMed merger and $490 million financing
FROM THE WIRE · FINANCE.YAHOO.COM
Mentari Therapeutics, Inc. Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically validated pathways and have potential to address the two-thirds of people who have a suboptimal response to…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe Nasdaq listing and $490 million of capital provide runway into 2029.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Two private placements raised gross proceeds of $490 million.
- 02Shares begin trading on Nasdaq under MTRI from November 9, 2026.
- 03Initial MT-001 data is expected mid-2027, and MT-002 filing in Q1 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets